Hunter syndrome with hyperthyroidism: a 16 month follow-up reprt
Abstract
Mucopolysaccharidosis (MPS) is a rare genetic disorder caused by a deficiency in the activity of lysosomal enzymes required for glycosaminoglycan (GAG) degradation. An accumulation of GAG in many organs results in progressive cellular damage, and clinically results in joint stiffness, airway and cardiac as well as, mental and hearing impairments. Incidence of MPS was reportedly 2.04 per 100,000 live births, but varies depending on type and region. In Taiwan, MPS type II was the most prevalent MPS, with an incidence of 1.07 per 100,000 live births.1 MPS is generally inherited in an autosomal recessive pattern, with the exception of MPS II, which is X-linked recessive.2 There are seven types of MPS (MPS I, II, III, IV, VI, VII, and IX), based on enzyme deficits.3 The types of MPS with their enzyme deficiencies are listed in Table 1.
Mucopolysaccharidosis shows wide clinical heterogenity, and is, therefore, difficult to diagnose. Skeletal involvement in MPS include coarse face, loss of joint range of motion, restricted mobility, and slowed growth leading to short stature. Other signs and symptoms include vision and hearing loss, recurrent respiratory infections, obstructive sleep apnea, hepatosplenomegaly, umbilical and inguinal hernia, hydrocephalus, spinal cord compression, and cognitive impairment.2,4 Patients with suspected MPS should have urinary GAG laboratory testing and enzyme activity assays in tissue (blood or fibroblasts). Urinary elevation of GAG, as compared with GAG levels expected in age-matched normal subjects, is the first diagnostic approach. The definitive specific diagnosis for MPS is based on enzyme activity assays from cultured fibroblasts, leukocytes, plasma, or serum.2,5,6 The MPS patients require multidiciplinary subspeciality management, including ENT, orthopedics, cardiology, pulmonary, growth and development, and physiotherapy. Specific treatments for MPS are hematopoietic stem cell transplantation (HSCT) and enzyme-replacement therapy (ERT) with recombinant human enzymes for MPS I, II, and VI.3,6,7,8 Life expectancies in MPS may vary among types, but generally are markedly reduced. Patients with MPS III and VII and severe forms of MPS I and MPS II have mental retardation. Patients with MPS II usually survive until only the second decade of life, with respiratory failure as the leading cause of death (56%), followed by cardiac failure (18%).9,10
References
Lin HY, Lin SP, Chuang CK, Niu DM, Chen MR, Tsai FJ, et al. Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004. Am J Med Genet A. 2009;149:960-4. https://doi.org/10.1002/ajmg.a.32781 PMid:19396827
Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology. 2011;50:4-12. https://doi.org/10.1093/rheumatology/ker394 PMid:22210669
Valayannopoulos V, Wijburg FA. Therapy for the mucopolysaccharidoses. Rheumatology. 2011;50:49-59. https://doi.org/10.1093/rheumatology/ker396 PMid:22210671
Lehman TJ, Miller N, Norquist B, Underhill L, Keutzer J. Diagnosis of the mucopolysaccharidoses. Rheumatology. 2011;50:41-8. https://doi.org/10.1093/rheumatology/ker390 PMid:22210670
Burton BK, Giugliani R. Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls. Eur J Pediatr. 2012;171:631-9. https://doi.org/10.1007/s00431-012-1703-y PMid:22383073 PMCid:PMC3306562
Noh H, Lee JI. Current and potential therapeutic strategies for mucopolysaccharidoses. J Clin Pharm Ther. 2014;39:215-24. https://doi.org/10.1111/jcpt.12136 PMid:24612142
Muenzer J, Beck M, Eng CM, Escolar M, Giugliani R, Guffon NH, et al. Multidisciplinary management of Hunter syndrome. Pediatrics. 2009;124:1228-39. https://doi.org/10.1542/peds.2008-0999 PMid:19901005
Beck M, Muenzer J, Scarpa M. Evaluation of disease severity in mucopolysaccharidoses. J Pediatr Rehabil Med. 2010;3:39-46. PMid:21791828
Guffon N, Heron B, Chabrol B, Feillet F, Montauban V, Valayannopoulos V. Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study. Orphanet J Rare Dis. 2015;10:43. https://doi.org/10.1186/s13023-015-0259-0 PMid:25887606 PMCid:PMC4407793
Giugliani R, Federhen A, Rojas MV, Vieira T, Artgalas O, Pinto LL, et al. Mucopolysaccharidosis I , II , and VI: brief review and guidelines for treatment. Genet Mol Biol. 2010;33:589-604. https://doi.org/10.1590/S1415-47572010005000093 PMid:21637564 PMCid:PMC3036139
World Health Organization.Training Course on Child Growth Asessment. Version 1-November 2006. Geneva: WHO; 2006.
Nour MA, Luca P, Stephure D, Wei XC, Khan A. Anterior hypopituitarism and treatment response in Hunter syndrome: a comparison of two patients. Case Rep Pediatr. 2016;2016:4328492. https://doi.org/10.1155/2016/4328492
Polgreen LE, Tolar J, Plog M, Himes JH, Orchard PJ, Whitley CB, et al. Growth and endocrine function in patients with Hurler syndrome after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41:1005-11. https://doi.org/10.1038/bmt.2008.20 PMid:18278070
Link B, de Camargo Pinto LL, Giugliani R, Wraith JE, Guffon N, Eich E, et al. Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey. Orthop Rev (Pavia). 2010;2:e16. https://doi.org/10.4081/or.2010.e16 PMid:21808707 PMCid:PMC3143973
Palmucci S, Attinà G, Lanza ML, Belfiore G, Cappello G, Foti PV, et al. Imaging findings of mucopolysaccharidoses: a pictorial review. Insights Imaging. 2013;4:443-59. https://doi.org/10.1007/s13244-013-0246-8 PMid:23645566 PMCid:PMC3731470
Tomatsu S, Monta-o AM, Oikawa H, Giugliani R, Harmatz P, Smith M, et al. Impairment of Body growth in mucopolysaccharidoses. In: Handbook of growth and growth monitoring in health and disease. New York: Springer International Publishing; 2012. p. 2091-117. https://doi.org/10.1007/978-1-4419-1795-9_126
Parini R, Jones SA, Harmatz PR, Giugliani R, Mendelsohn NJ. The natural history of growth in patients with Hunter syndrome: data from the Hunter Outcome Survey (HOS). Mol Genet Metab. 2016;117:438-46. https://doi.org/10.1016/j.ymgme.2016.01.009 PMid:26846156
Kamin W. Diagnosis and management of respiratory involvement in Hunter syndrome. Acta Paediatr. 2008;97:57-60. https://doi.org/10.1111/j.1651-2227.2008.00650.x PMid:18339190
Archer IM, Young ID, Rees DW, Oladimeji A, Wusteman FS, Harper PS. Carrier detection in Hunter syndrome. Am J Med Genet. 1983;16:61-9. https://doi.org/10.1002/ajmg.1320160111 PMid:6227239
Lin HY, Chuang CK, Huang YH, Tu RY, Lin FJ, Lin SJ, et al. Causes of death and clinical characteristics of 34 patients with mucopolysaccharidosis II in Taiwan from 1995-2012. Orphanet J Rare Dis. 2016;11:85. https://doi.org/10.1186/s13023-016-0471-6 PMid:27349225 PMCid:PMC4924312
Copyright (c) 2018 din alfina, Endy Paryanto Prawirohartono, Roni Naning, Neti Nurani
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Accepted 2018-12-14
Published 2018-12-14
